Cephalon offers up to $22M on Alba drug option; Neuralstem shares jump on orphan status;

@FierceBiotech: Investors ready to craft new biotechs out of Pfizer's discards. News | Follow @FierceBiotech

@JohnCFierce: Viehbacher says it's possible he could extend Genz talks past the 15th. Is he toying with us or did they hit a snag? |  Follow @JohnCFierce 

> Cephalon has agreed to pay $7 million upfront to gain an option on an experimental drug from Alba Therapeutics to treat celiac disease. Cephalon will provide a credit line to Alba for its mid-stage trial of the drug and will pay $15 million if the data persuades the biotech to pick up the option. Story

> An experimental ALS therapy at Neuralstem has gained orphan drug status, spurring a jump in its share price. Report

> Fluidigm prices its IPO at $13.50 a share, on the low end of its range. The company provides technology for genetic analysis work. Report

> UC San Francisco has opened its $123 million stem cell research center. Story

> Alexion Pharmaceuticals has acquired the IP for a treatment of a rare genetic disease from Germany's Orphatec. Article

And Finally... Microsponges derived from seaweed may help diagnose heart disease, cancers, HIV and other diseases quickly and at far lower cost than current clinical methods. Report